© Globe Newswire
15.01.2026
VXRT
LISTED
NASDAQ
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
News Preview
Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
COLL
LISTED
NASDAQ
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
News Preview
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disord...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
EXE
LISTED
TSX
Extendicare Announces January 2026 Dividend of C$0.042 per Share
News Preview
MARKHAM, Ontario, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of January 2026, which is payable on February 16, 2026 to shareholders of record at the close of business on January 30, 2026. This...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
15.01.2026
OSTX
LISTED
XASE
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year)Pre-specified pathway analysis strategy developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 demonstr...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
15.01.2026
IDXX
LISTED
NASDAQ
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
News Preview
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced two major advancements in veterinary cancer diagnostics: the expansion of its IDEXX Cancer Dx™ Panel to include canine mast cell tumor detection, starting mid-year 2026 in North America, and the rollout of FNA cytology on the IDEXX inVue Dx™ Cell...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
MDNA
LISTED
TSX
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
News Preview
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential for advanced cancer patients with no treatment options...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
AXSM
LISTED
NASDAQ
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
News Preview
NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.01.2026
CASI
LISTED
NASDAQ
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
News Preview
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant loss with no approved treatmentsU.S. IND previously approved by FDA for Phase 1 AMR study SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clin...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.01.2026
NVNO
LISTED
NASDAQ
enVVeno Medical Announces Reverse Stock Split
News Preview
IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock S...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
SANN
LISTED
SIX
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
News Preview
Commercial launch in Switzerland anticipated in H2 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
SAN
LISTED
EURONEXT
Press Release: Myqorzo and Redemplo approved in China
News Preview
Myqorzo and Redemplo approved in China...
Themefolio
Profiler
Peergroup
© PR Newswire
15.01.2026
2269
LISTED
HKSE
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
News Preview
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clientsComplex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
15.01.2026
CORT
LISTED
NASDAQ
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information perti...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2026
6855
LISTED
HKSE
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
News Preview
ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced tha...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
JNJ
LISTED
NYSE
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
News Preview
TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need populationMajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapseRARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple m...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
TEVA
LISTED
TLV
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the New England Journal of Medicine (NEJM) has published pivotal Phase 3 data on AJOVY, highlighting its efficacy and safety in children and adolescents...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
CNTA
LISTED
NASDAQ
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
News Preview
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
BBIO
LISTED
NASDAQ
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
News Preview
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
DNTL
LISTED
TSX
Dentalcorp Announces Closing of Acquisition by Investment Funds Affiliated with GTCR
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL) today announced the successful completion of the previously-announced statutory plan of arrangement (the “Arrangement”) whereby a newly formed acquisition vehicle affiliated with GTCR LLC (“GTCR”) acquired all of Dentalcorp’s issued and outstanding subordinate voting shares and m...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release
14 January 2026
WORLDWIDE HEALTHCARE TRUST PLC
(the "Company")
...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
AGL
LISTED
NYSE
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages agilon health, inc. (AGL) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
SAN
LISTED
EURONEXT
Sanofi: Information concerning the total number of voting rights and shares - December 2025
News Preview
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2026
RHK
LISTED
XETR
RHÖN-KLINIKUM Aktiengesellschaft adjusts the EBITDA forecast for financial year 2025
News Preview
Ad hoc announcement pursuant to Article 17 MAR
RHÖN-KLINIKUM Aktiengesellschaft
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
ISIN DE0007042301 / WKN 704230
Bad Neustadt a. d. Saale | 14 January 2026
RHÖN-KLINIKUM Aktiengesellschaft adjusts the EBITDA forecast for the financial year 2025
RHÖN-KLINIKUM Aktiengesellschaft announces that the......
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
ERAS
LISTED
NASDAQ
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /CNW/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a loomin...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
ERAS
LISTED
NASDAQ
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
News Preview
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
COSM
LISTED
NASDAQ
Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
News Preview
CHICAGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research (“Zacks”) has initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
EGRX
LISTED
NASDAQ
Eagle Pharmaceuticals Announces Divestiture of Barhemsys
News Preview
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France....
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
YCBD
LISTED
XASE
cbdMD Announces Strategic Acquisition of Bluebird Botanicals
News Preview
CHARLOTTE, N.C., Jan. 14, 2026 /PRNewswire/ -- cbdMD, Inc (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, announced today the closing of the acquisition of substantially all of the assets of Bluebird Botanicals, one of the longest-standing brands in the CBD industry, providing an established and complementary revenue...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
000220
LISTED
KOE
Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion
News Preview
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on the UCLA campus, strengthening the company's presence in the United States pet and animal health market....
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
CVS
LISTED
NYSE
CVS Health Foundation Grants the American Diabetes Association $2.6 Million to Expand Maternal Diabetes Program Across Two Additional NYC Communities
News Preview
Building on 18 months of proven success, the initiative will scale evidence-based solutions to improve pregnancy and postpartum outcomes for New YorkersNEW YORK, Jan. 14, 2026 /PRNewswire/ -- The CVS Health Foundation granted the American Diabetes Association® (ADA) $2.6 million to expand its maternal health initiative to two additional communitie...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
PWR
LISTED
CSE
Captiva Verde Welcomes Greg Reitman as Chairman of the Captiva Verde Media and Charity Advisory Board
News Preview
Coquitlam, British Columbia--(Newsfile Corp. - January 14, 2026) - Captiva Verde Wellness Corp. (CSE: PWR) (OTC Pink: CPIVF) (the "Company or Captiva") announces that it welcomes Greg Reitman as Chairman of the Captiva Verde Media and Charity Advisory Board. Greg is an American Film Director, Producer, Screenwriter, National Best-Se...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
HNGE
LISTED
NYSE
Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026
News Preview
Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026.
Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) th...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
IBRX
LISTED
NASDAQ
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ,...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
IBRX
LISTED
NASDAQ
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
CRNO B
LISTED
STO
Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases
News Preview
GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the publication of the first peer-reviewed manuscript describing CS014, a new chemical entity (NCE) and...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ISRG
LISTED
NASDAQ
Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
News Preview
SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
FEMY
LISTED
NASDAQ
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
News Preview
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("N...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ADIL
LISTED
NASDAQ
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
News Preview
New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information New patent based on treatment of populations identified to be particularly responsive to ondansetron treatment after examination of Adial’s clinical data and information...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ORNBV
LISTED
HEL
Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE 14 JANUARY 2026 at 16:00 EET ...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
PHRM
LISTED
CSE
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
News Preview
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategi...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
SOL
LISTED
CSE
SOL Global Announces Completion of Share Consolidation
News Preview
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that, further to its press release dated December 8, 2025, and following approval by a majority vote of the Company's Board of Directors, it has completed a share consolidation (the "...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
AVAH
LISTED
NASDAQ
Aveanna Healthcare Holdings Announces Updated Full Year 2025 and Initial Full Year 2026 Guidance
News Preview
ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced updated full year guidance for fiscal year 2025 (year ended January 3, 2026) and its initial full year guidance for fis...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
LENZ
LISTED
NASDAQ
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
News Preview
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
NNOX
LISTED
NASDAQ
Nanox Expands in Europe with New Nanox.ARC Distribution Engagement in Serbia, Montenegro, and Bosnia and Herzegovina
News Preview
Collaboration with Adriamed drives commercial expansion and strengthens Nanox’s regional leadership...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
OPTI
LISTED
CSE
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on Janua...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
ANRO
LISTED
NYSE
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
News Preview
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. Th...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
ACB
LISTED
NASDAQ
Aurora Achieves Significant Progress in Disease Resistance Research
News Preview
NASDAQ | TSX: ACBAs a leading global medical cannabis company, advancements in breeding, testing and production trials for powdery mildew-resistant cultivars reinforce Aurora's leadership in cannabis scienceEDMONTON, AB, Jan. 14, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company,...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
ACB
LISTED
NASDAQ
Aurora Achieves Significant Progress in Disease Resistance Research
News Preview
NASDAQ | TSX: ACBAs a leading global medical cannabis company, advancements in breeding, testing and production trials for powdery mildew-resistant cultivars reinforce Aurora's leadership in cannabis scienceEDMONTON, AB, Jan. 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis c...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
ITGR
LISTED
NYSE
Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting
News Preview
~ Attendees Invited to Visit Integer at Booth #115 ~ ~ Attendees Invited to Visit Integer at Booth #115 ~...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
IXHL
LISTED
NASDAQ
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026
News Preview
Incannex Healthcare highlighted 2025 clinical, regulatory and financial milestones and outlined 2026 priorities supported by an extended cash runway....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
NDTP
LISTED
OTC
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., to Launch Dog Gone Odor® on Chewy and Amazon, Expanding its Rapidly Growing Biosafety Catalog
News Preview
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., to Launch Dog Gone Odor® on Chewy and Amazon....
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
OSTX
LISTED
XASE
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
News Preview
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026)OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determin...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2026
UNH
LISTED
NYSE
UnitedHealthcare to Support Rural Hospitals with Accelerated Medicare Advantage Payments, Providing Immediate Cash-Flow Relief
News Preview
UnitedHealthcare today announced the launch of its Rural Payment Acceleration Pilot, a targeted initiative designed to support independent rural hospitals facing financial challenges.
Over the next six months, the pilot will accelerate Medicare Advantage payment timelines by 50%, from less than 30 days to less than 15 days, on average. The pilot...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
LH
LISTED
NYSE
Labcorp Declares Quarterly Dividend
News Preview
BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2026
BDX
LISTED
NYSE
BD Names Shawn Bevec as Senior Vice President of Investor Relations
News Preview
FRANKLIN LAKES, N.J., Jan. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shawn Bevec has been named senior vice president of investor relations, effective Jan. 20....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
NRXP
LISTED
NASDAQ
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
News Preview
WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has licensed Real World Evidence (RWE) drawn from over 70,000 patients in the United States who were treated with either intravenous ketamine or nasal S-ketamine for depression and suici...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2026
SDZ
LISTED
XWSX
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
News Preview
Sandoz Group AG
/ Key word(s): Regulatory Approval
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes 14.01.2026 / 12:00 CET/CEST
Biosimilar Ondibta® (insulin glargine) approved for treatment of diabetes mellitus across all indicati......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2026
CCCC
LISTED
NASDAQ
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
News Preview
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2026
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces Secured Real Estate Location and Franchisee for Shawnessey Village, Calgary
News Preview
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce that its Heal Wellness brand ("Heal") has secured both a franchisee and a real estate location in Shawnessey Village, a high-tra...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
